Versus EmtricitabinePlus TDF - HIVandHepatitis.com

More documents

Recommendations

Info

Baseline Genotypic Analysis Patient Population N All Enrolled 105 Patients with ADV-Resistance Mutations at Baseline 10 (9.5%) rtA181V 2 rtN236T 2 rtA181T/V + rtN236T 4 rtA181T 2 Patients with LAM-Resistance Mutations at Baseline 13 (12.4%) rtM204V/I 1 rtL180M+rtM204V/I 12 All patients with Mutations at Baseline 23 (22%) * population sequencing
Mean HBV DNA (Log 10 c/mL) by Baseline ADV-R and Treatment 9 8 ADV Res TDF Not ADV Res TDF Treatment ADV Res FTC/TDF Not ADV Res FTC/TDF Mean HBV DNA (Log 10 Copies/mL) 7 6 5 4 3 2 LLOQ 1 0 4 8 12 24 36 48 60 72 84 96 108 120 132 144 156 168 Weeks on Study Not ADV Res FTC/TDF N= 50 50 48 50 50 48 48 48 46 44 45 43 42 41 42 42 40 Not ADV Res TDF N= 45 45 43 44 44 44 44 43 42 42 42 40 40 38 37 34 36 ADV Res FTC/TDF N= 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 ADV Res TDF N= 8 8 8 8 8 8 8 8 8 7 8 8 8 8 8 8 8
Page 1 and 2: Tenofovir Disoproxil Fumarate (TDF)
Page 3 and 4: Introduction • Virologic suppress
Page 5 and 6: Key Eligibility Criteria • 18-69
Page 7 and 8: Patient Disposition at 168 Weeks N=
Page 9 and 10: Primary Efficacy Analysis: Comparis
Page 11: Week 168 Serology Results* TDF FTC/
Page 15 and 16: Virology Analysis Plan for Study 10
Page 17 and 18: Proportion
Page 19 and 20: Conclusions • Both treatment stra
Page 21 and 22: Back UP
Page 23 and 24: Proportion with HBV DNA 10 7 c/mL >
Page 25: Proportion of Patients with ALT Nor

Versus EmtricitabinePlus TDF - HIVandHepatitis.com

Create successful ePaper yourself

Delete template?

Save as template?